The SoluPro E.coli manufacturing platform will be applied to two of Sanofi’s biologic candidates under a partnership deal with AbSci. Financial details of the deal have not been divulged, but the French Big Biopharma firm will use AbSci’s SoluPro expression platform on two of its molecules. The work will be undertaken at AbSci’s facilities in Vancouver, Washington, USA. According to AbSci, the platform can accelerate the time it takes to get new drugs to market through ultra-high titers of soluble,…

After an initial collaboration in 2015, Selexis has signed commercial license agreements with Agenus to develop research cell banks for additional antibody programs. In 2015, clinical-stage immuno-oncology firm Agenus selected cell line development firm Selexis to collaborate on its lead anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) programs. Four years on and the firms have extended the deal to include the use of Selexis’ SUREtechnology platform with additional novel single agent and combination therapies. “Under the expanded collaboration, Selexis will continue to…